Hello Bankers !!
🔴 🔴 CAIIB ABM 2025 | Clear हुआ या नहीं?
Join Priyanshu Sir & Suprabha Ma’am as they break down the paper,
share insights, and discuss the cut-off trends!
🔥 Don’t miss this detailed analysis – find out how your exam went!
https://www.youtube.com/watch?v=RKl-slDxZyg
Join Priyanshu Sir & Suprabha Ma’am as they break down the paper,
share insights, and discuss the cut-off trends!
🔥 Don’t miss this detailed analysis – find out how your exam went!
https://www.youtube.com/watch?v=RKl-slDxZyg
Please open Telegram to view this post
VIEW IN TELEGRAM
❤6
Hey Bankers! 🙌
CAIIB June 2025 ABM 3rd Shift exam analysis is out now!
Join Priyanshu & Suprabha Ma’am as they share the key highlights and break down the tough spots from today’s paper.
Get their expert tips to help you prepare better for the next shifts.
Let’s tackle this together! 💪
Don’t miss it — watch now and stay ahead!
Live Now-🔴 🔴
https://www.youtube.com/watch?v=jyFnfYdv5I0
CAIIB June 2025 ABM 3rd Shift exam analysis is out now!
Join Priyanshu & Suprabha Ma’am as they share the key highlights and break down the tough spots from today’s paper.
Get their expert tips to help you prepare better for the next shifts.
Let’s tackle this together! 💪
Don’t miss it — watch now and stay ahead!
Live Now-
https://www.youtube.com/watch?v=jyFnfYdv5I0
Please open Telegram to view this post
VIEW IN TELEGRAM
❤1
https://youtube.com/shorts/kPGKJYw8A6U?feature=shared please share your sscore please
YouTube
CAIIB ABM Analysis Shift 1 Paper Review #caiib #caiin2025 #shorts #result
JAIIB Virtual Library (Free for all) - https://forms.gle/Ro6ZKTUhSWNRqWbx9CAIIB Virtual Library (Free for all) - https://forms.gle/L7knJEUhucTnnJaS9📚 JAIIB...
❤12
ABM Provisional Scorecard is now Out.!!!
❤14
The ABFM class of Module C will be tomorrow from 4-6.30 pm
CASE STUDY: Three-Stage Growth Valuation – Zenith Biocare Ltd.
Zenith Biocare Ltd. currently reports Earnings per Share (EPS) of ₹12. The management anticipates the following growth trajectory:
🔹 Stage 1: High-Growth Phase (Years 1–4)
EPS will grow at 30% annually for the next 4 years.
Dividend payout ratio remains constant at 20%.
Cost of equity: 18%
🔹 Stage 2: Transition Phase (Years 5–7)
EPS growth rate will decline linearly from 30% to 18% over these 3 years.
Dividend payout will increase linearly from 20% to 50%.
Cost of equity will decrease by 1% annually, starting from 18% in year 5.
🔹 Stage 3: Stable Phase (Year 8 onwards)
EPS growth stabilizes at 6% annually, indefinitely.
Dividend payout stabilizes at 60%
Cost of equity: 15%
You are required to estimate the intrinsic value of the share using the Three-Stage Dividend Discount Model.
Zenith Biocare Ltd. currently reports Earnings per Share (EPS) of ₹12. The management anticipates the following growth trajectory:
🔹 Stage 1: High-Growth Phase (Years 1–4)
EPS will grow at 30% annually for the next 4 years.
Dividend payout ratio remains constant at 20%.
Cost of equity: 18%
🔹 Stage 2: Transition Phase (Years 5–7)
EPS growth rate will decline linearly from 30% to 18% over these 3 years.
Dividend payout will increase linearly from 20% to 50%.
Cost of equity will decrease by 1% annually, starting from 18% in year 5.
🔹 Stage 3: Stable Phase (Year 8 onwards)
EPS growth stabilizes at 6% annually, indefinitely.
Dividend payout stabilizes at 60%
Cost of equity: 15%
You are required to estimate the intrinsic value of the share using the Three-Stage Dividend Discount Model.
❤8